Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Takeda's UC, Crohn's Drug Gets OK from EU Committee

March 21, 2014 11:08 am | News | Comments

Takeda announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has issued a positive opinion for Entyvio (vedolizumab) for the treatment of adults with ulcerative colitis (UC) and Crohn's disease (CD). Read more...

TOPICS:

Oral Chemotherapy Trial Launched in New Zealand

March 21, 2014 11:00 am | News | Comments

Kinex Pharmaceuticals announced that the company has received regulatory and ethics approvals to initiate the first clinical study of an oral form of paclitaxel (Oraxol) in Dunedin Hospital in Otago, New Zealand. Read more...        

TOPICS:

CHMP Recommends EU Approval of Empagliflozin for Diabetes

March 21, 2014 10:41 am | News | Comments

Boehringer Ingelheim and Eli Lilly and Co. announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of empagliflozin in adults with type 2 diabetes. Read more...

TOPICS:
Advertisement

UK Panel Backs Bexsero for National Immunization Program

March 21, 2014 10:24 am | News | Comments

Novartis announced that the Joint Committee on Vaccination and Immunization in the UK has recommended the inclusion of Bexsero (Meningococcal Group B Vaccine) in the National Immunization Program. Read more...           

TOPICS:

Canada Gives First Approval of Biogen Hemophilia Drug

March 21, 2014 10:04 am | News | Comments

Biogen Idec announced that Health Canada has approved Alprolix for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. Read more...           

TOPICS:

Janssen Halts Schizophrenia Drug Trial on Positive Efficacy

March 20, 2014 3:10 pm | News | Comments

Janssen Research & Development announced that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of an investigational schizophrenia treatment. Read more...

TOPICS:

FDA Names Pfizer MenB Vaccine as Breakthrough Therapy

March 20, 2014 3:02 pm | News | Comments

Pfizer announced that the FDA has granted Breakthrough Therapy designation to Pfizer’s vaccine candidate, bivalent rLP2086, currently under investigation for the prevention of invasive meningococcal disease due to Neisseria meningitidis serogroup B. Read more...

TOPICS:

Hawaii Sues BMS, Sanofi Over Plavix

March 20, 2014 2:43 pm | by Jennifer Sinco Kelleher | News | Comments

Hawaii's attorney general is suing the makers of a widely prescribed blood thinner that he says a significant portion of the state's population has difficulty metabolizing. The suit names Bristol-Myers Squibb and Sanofi-Aventis as defendants. Read more...

TOPICS:
Advertisement

Agenus-GSK Lung Cancer Drug Disappoints in Trial

March 20, 2014 2:18 pm | News | Comments

Shares of Agenus tumbled more than 13% Thursday before markets opened and after the biopharmaceutical released more ineffective study results from its collaboration with GlaxoSmithKline. Read more...               

TOPICS:

How Personalized Medicine Works: Bananas and Biomarkers

March 20, 2014 11:13 am | Videos | Comments

In today's video, Andrew Wiecek discusses how personalized medicine works by highlighting the importance of biomarkers (and bananas) and showing that they play a key role in identifying genetic variations associated with disease.       

TOPICS:

Study Finds Stem Cell Combo Therapy Improves TBI Outcomes

March 20, 2014 10:45 am | News | Comments

In an effort to find an effective therapy for traumatic brain injury, neuroscientists have conducted several preclinical studies aimed at finding combination therapies to improve TBI outcomes. Read more...              

TOPICS:

Court Tosses $1.2B Risperdal Judgment Against J&J

March 20, 2014 10:25 am | by Chuck Bartels | News | Comments

The Arkansas Supreme Court on Thursday overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker's marketing of the antipsychotic drug Risperdal. Read more...             

TOPICS:

Qiagen TB Test to Aid Disease Control in China

March 20, 2014 10:22 am | News | Comments

Qiagen NV announced the commercial launch in China of its QuantiFERON-TB Gold In-Tube, a blood test that accurately identifies people infected with Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB). Read more...       

TOPICS:

Eisai Launches Academic Partnership to Discover Filariasis Drugs

March 20, 2014 9:56 am | News | Comments

Eisai announced that it has entered a collaboration with the Liverpool School of Tropical Medicine and the University of Liverpool to identify new drugs that are effective against two major types of the parasitic tropical disease filariasis. Read more...

TOPICS:

Actavis Settles Daytrana Patent Challenge

March 20, 2014 9:48 am | News | Comments

Actavis announced that it has entered into an agreement with Noven Pharmaceuticals Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana. Read more...                 

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading